Gil Beyen, Erytech Pharma CEO

French pen­ny stock will no longer knock on FDA door for ap­proval in a cer­tain type of blood can­cer

Things are not look­ing up for the French biotech Ery­tech Phar­ma.

The com­pa­ny is knock­ing off its plan to get FDA ap­proval for its drug Gras­pa in hy­per­sen­si­tive acute lym­phoblas­tic leukemia (ALL), fol­low­ing feed­back from the reg­u­la­tors, it said in a press re­lease Wednes­day af­ter­noon. ALL is the com­mon type of child­hood can­cer di­ag­nosed in ap­prox­i­mate­ly 5,000 new cas­es each year in the Unit­ed States.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.